Spruce Biosciences, INC 10-Q quarterly reports

Spruce Biosciences, Inc. filed its Form 10-Q for the period ending June 30, 2026, detailing continued net losses and a focus on advancing its TA-ERT therapy for MPS IIIB, while highlighting the need for substantial additional financing.

Spruce Biosciences, Inc. filed its Q1 2026 Form 10-Q, detailing financial results, operational updates, and forward-looking statements, with a net loss of $12.3 million.

Spruce Biosciences reports Q3 2025 financial results, highlighting a strategic pivot to TA-ERT for Sanfilippo Syndrome Type B, FDA Breakthrough Therapy Designation, and a recent $50 million private placement to address liquidity concerns.

Spruce Biosciences reports substantial doubt about its ability to continue as a going concern, alongside a Nasdaq delisting and significant workforce reduction, despite positive clinical data for TA-ERT.

Spruce Biosciences reports Q1 2025 results, highlighting a shift towards tralesinidase alfa (TA-ERT) development for Sanfilippo Syndrome Type B amidst delisting concerns and substantial doubt about its ability to continue as a going concern.

Spruce Biosciences reports a net loss of $8.7 million for Q3 2024, with updates on clinical trials for tildacerfont in CAH, PCOS, and MDD.

Spruce Biosciences reports a net loss of $20.8 million for the first half of 2024, while advancing its clinical programs for tildacerfont.

Spruce Biosciences reports a net loss of $11.6 million for the first quarter of 2024, with updates on clinical trials for tildacerfont.